Online supplementary table: Most commonly used biological agents in paediatric patients

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Generic name(Abbreviation) | Mechanism of action | Route  | Standard dosage | Approval for paediatric patients |
| EMA | FDA |
| Etanercept(ETA) | Fusion protein TNF receptor linked to FcIgG1 | SC  | * 0.4 mg/kg twice weekly
* Maximum 50 mg/dose
 | Yes | Yes |
| Infliximab(INF) | Chimeric monoclonal anti-TNF antibody(mouse-human) | IV | * 5 mg/kg, induction phase at 0, 2, 6 weeks, then every 8 weeks
 | Yes | Yes  |
| Adalimumab(ADA) | Human monoclonal anti-TNF antibody | SC | * weight <30 kg: 20 mg every 2 weeks
* weight >30 kg: 40 mg every 2 weeks
 | Yes | Yes |
| Anakinra(ANK) | IL-1 receptor antagonist | SC | * 1 mg/kg every day
* Maximum 100 mg/dose
 | No | No |
| Tocilizumab(TCZ) | Anti-IL-6 receptor antibody | IV | * weight <20 kg: 12 mg/kg every 2 weeks
* weight >20 kg: 8 mg/kg every 2 weeks
 | Yes | Yes |
| Abatacept(ABA) | Modulator of T-cell co-stimulation  | IV | * 10 mg/kg, induction phase at 0, 2, 4 weeks, then every 4 weeks
 | Yes | Yes |
| Rituximab(R) | Anti-CD20 antibody  | IV | * Two doses of 750 mg/m2 at week 0 and 2
* Maximum 1000 mg/dose

 | No | No  |

IV = intravenous, SC = subcutanous, TNF = tumour necrosis factor, IL = interleukin